You are about to leave doptelethcp.com and go to an external page.
Please note that Sobi is not responsible for the content of the website you are about to visit.
CONTINUEGo back
You are about to leave doptelethcp.com and go to an external page.
Please note that Sobi is not responsible for the content of the website you are about to visit.
CONTINUEGo back
This information is intended for healthcare professionals in the United States.
Are you a healthcare professional?
Yes
NoDiscover the Copay Assistance Program
Terms and Conditions
DOPTELET IS THE FASTEST-GROWING TPO-RA1**
Based on year-over-year financial market growth data for TPO-RAs from fiscal year 2021 compared to fiscal year 2022.1
Reference: 1. Data on file. TPO-RA Market Growth. 2023: Sobi, Inc.
DOPTELET NOW HAS PARITY ACCESS WITH ELTROMBOPAG AT SOME OF THE LARGEST COMMERCIAL PLANS1
Use our look-up tool to see if your commercial plan is eligible for Doptelet.
Reference: 1. Data on file. CAM Conversion Guide. 2022: Sobi, Inc.
Doptelet® (avatrombopag) is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.1
Doptelet is a thrombopoietin receptor agonist (TPO-RA) that works with the body to increase platelet production.1
You may see platelet counts rise in as few as 8 days.1 To read more about the clinical trials and results for Doptelet, visit our efficacy page.
It is recommended to start all patients with a dosage strength of 20 mg once daily and dose adjust as needed. Please note that 20 mg is the initial dose regimen for all patients except those taking Moderate or Strong Dual Inducers or Moderate or Strong Dual Inhibitors of CYP2C9 and CYP3A4. Depending on your patient’s treatment goal, the dose could be titrated up or down.1 Refer to the Titration Calculator or the Full Prescribing Information for more details on Titration.
It is recommended that patients take it as soon as they remember, but they should not take 2 doses at one time to make up for a missed dose. It is advised patients take their next Doptelet dose at their usual scheduled time.1 Refer to the Full Prescribing Information for more information on Doptelet dosing.
Doptelet may affect the way other medications work, and other medications may affect the way Doptelet works. Dose adjustments are recommended for adult patients living with low platelets in chronic ITP taking moderate or strong dual CYP2C9 and CYP3A4 inducers or inhibitors.1 Refer to the Full Prescribing Information to learn more.
Patients should store Doptelet tablets in the original package and at room temperature meaning between 68oF to 77oF (20oC to 25oC).1 Please remind patients to store Doptelet, and all medicines, out of the reach of children.
Thrombotic/Thromboembolic Complications: DOPTELET is a thrombopoietin (TPO) receptor agonist and TPO receptor agonists have been associated with thrombotic and thromboembolic complications in patients with chronic liver disease or chronic immune thrombocytopenia. Monitor platelet counts. Monitor for signs and symptoms of thromboembolic events and institute treatment promptly.
In clinical trials, the most common adverse reactions, which occurred in 10% or more adults living with low platelets in chronic ITP treated with Doptelet, were: headache, fatigue, contusion, epistaxis, upper respiratory tract infection, arthralgia, gingival bleeding, petechiae, and nasopharyngitis.1 To read more about adverse reactions with Doptelet, visit our safety page.
Doptelet can be taken with any kind of food to help your patients reach their target platelet count. Please note that food is required when taking Doptelet.1
Yes, the Doptelet Copay Assistance Program is for eligible patients who have commercial prescription insurance. Patients may pay as little as $0 per prescription, up to a maximum of $15,000 per calendar year. Visit the access page to view terms and conditions, and learn more about access and reimbursement support from Doptelet Connect.
Immune thrombocytopenia (ITP) is an immune disorder characterized by low platelet counts (<100×109/L). The mechanisms of ITP can involve both increased platelet destruction and impaired platelet production.2
Common symptoms of immune thrombocytopenia include bruising, petechiae, bleeding, and fatigue.3
Our support specialists can help answer your questions about Doptelet and access options — call us at
833-368-2663.
Monday–Friday 8 AM–8 PM ET.
INDICATION
DOPTELET® (avatrombopag) is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.
IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
Thrombotic/Thromboembolic Complications. DOPTELET is a thrombopoietin (TPO) receptor agonist and TPO receptor agonists have been associated with thrombotic complications in patients with chronic liver disease (0.4%; (1/274) in DOPTELET-treated patients) and thromboembolic complications in patients with chronic immune thrombocytopenia (7%; (9/128) in DOPTELET-treated patients). Portal vein thrombosis has been reported in patients with chronic liver disease, and thromboembolic events (arterial and venous) have been reported in patients with chronic immune thrombocytopenia treated with TPO receptor agonists.
Consider the potential increased thrombotic risk when administering DOPTELET to patients with known risk factors for thromboembolism, including genetic prothrombotic conditions.
DOPTELET should not be administered to patients with chronic liver disease or chronic immune thrombocytopenia in an attempt to normalize platelet counts. Monitor platelet counts, and for signs and symptoms of thromboembolic events and institute treatment promptly.
Serious Adverse Reactions
Serious adverse reaction that occurred more frequently in patients treated with DOPTELET (9%; 12/128) compared to placebo (5%; 1/22) was headache, occurring in 1.6% (2/128).
Adverse Reactions
The most common adverse reactions (≥10%) in patients with chronic immune thrombocytopenia were headache, fatigue, contusion, epistaxis, upper respiratory tract infection, arthralgia, gingival bleeding, petechiae, and nasopharyngitis.
Postmarketing Experience
Following the approval of DOPTELET, hypersensitivity reactions involving the immune system, including, but not limited to, pruritus, rash, choking sensation, swollen face, and swollen tongue have been reported.
These are not all the possible risks associated with DOPTELET. Please see Full Prescribing Information for DOPTELET at www.doptelethcp.com
To report suspected adverse reactions, contact Sobi North America at 1-866-773-5274 or FDA at 1-800-FDA-1088.
For WAC pricing, visit doptelethcp.com/wac-pricing.
INDICATION
DOPTELET® (avatrombopag) is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.
This website uses cookies. By continuing to use this website, you consent to our use of these cookies.